{
    "title": "114_hr639",
    "content": "The Act titled \"Improving Regulatory Transparency for New Medical Therapies Act\" amends the Federal Food, Drug, and Cosmetic Act regarding the scheduling of substances in new FDA-approved drugs. Approval of a drug under the Controlled Substances Act will not take effect until the interim final rule controlling the drug is issued. The term \"date of approval\" refers to the later of the date of the application or the issuance of the interim final rule. The Act amends the Public Health Service Act regarding the approval of biological products under the Controlled Substances Act. Approval of an application will not take effect until the interim final rule controlling the product is issued. The \"date of approval\" is determined by the issuance of the interim final rule. The approval date of an application for a biological product under the Controlled Substances Act is determined by the issuance of the interim final rule controlling the product. The approval date of an application under the Controlled Substances Act is determined by the issuance of the interim final rule controlling the drug. Conditional approval of the application will not take effect until the interim final rule is issued. The approval date of an application under the Controlled Substances Act is determined by the issuance of the interim final rule controlling the drug. Conditional approval of the application will not take effect until the interim final rule is issued. Additionally, for designated new animal drugs, the date of approval is based on the issuance of the interim final rule. The approval date for designated new animal drugs is determined by the issuance of the interim final rule controlling the drug under the Controlled Substances Act. The Secretary of Health and Human Services may recommend scheduling the drug in schedule II, III, IV, or V, and the Attorney General must issue an interim final rule within 90 days. The Attorney General must issue an interim final rule controlling the drug within 90 days of receiving the scheduling recommendation from the Secretary of Health and Human Services. The rule becomes immediately effective without needing a demonstration of good cause. The Attorney General must issue an interim final rule controlling the drug within 90 days of receiving the scheduling recommendation from the Secretary of Health and Human Services, without needing to demonstrate good cause. Interested persons can comment and request a hearing before a final rule is issued in accordance with specific criteria. The product must be approved or indexed under relevant provisions of the Public Health Service Act or Federal Food, Drug, and Cosmetic Act to have permission for commercial marketing or use. The term 'covered date' refers to the later of the approval date under specific sections of the Acts or the date of issuance of the interim final rule controlling the drug under the Controlled Substances Act. The Attorney General must register applicants for manufacturing controlled substances for clinical trials within specific timeframes. Additionally, there are regulations for re-exportation among members of the European Economic Area under the Controlled Substances Import and Export Act. Section 1003 of the Controlled Substances Import and Export Act (21 U.S.C. 953) is amended to allow for the re-exportation of controlled substances among members of the European Economic Area, with specific conditions to be met by each subsequent country involved. The Controlled Substances Import and Export Act is amended to allow re-exportation among members of the European Economic Area, with specific conditions to be met by each subsequent country involved. The Controlled Substances Import and Export Act is amended to allow re-exportation among European Economic Area countries without restrictions on time or information disclosure. The curr_chunk is about the roles of the Speaker of the House of Representatives and the Vice President of the United States as President of the Senate."
}